Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
The biggest IPO of 2024 so far in Europe has delivered a welcome bounce in the aftermarket
-
Galderma will provide the European IPO market with another important data point when it begins trading on Friday
-
The final size of the base deal will be Sfr2bn after the IPO was priced at the top of the range
-
The biggest IPO of the year so far in Europe is multiple times covered, according to sources
-
KBRA expects to upgrade deal if merger with Orangetheory goes through
-
US drug maker's stake in Haleon set to fall to 24%